Filing Flows › Citius Oncology (CTOR) › Q3 FY26
Citius Oncology (CTOR) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Aug 14, 2026
Citius Oncology (CTOR) reported revenue of $1.5M for the third quarter fiscal 2026 (Q3 FY26) and -10% from the quarter before. Operating margin was -583.5%, net loss $8.9M (597.4% of revenue).
Citius Oncology, Q3 FY26: revenue $1.5M, operating margin -583.5%, net loss $8.9M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | -10% | — |
| Operating profit | −$8.7M | — | — |
| Net earnings | −$8.9M | — | — |
| Operating cash flow | −$2.7M | — | — |
What changed
Revenue was $1.5M in Q3 FY26, down 10% from the previous quarter.
Gross margin was 67.1%. Operating costs exceeded revenue by $8.7M, an operating margin of -583.5%. The quarter ended with a net loss of $8.9M, narrower than the previous quarter's $26.6M loss.
Operating cash flow was −$2.7M. Non-cash charges added back $3.6M of share-based compensation. Working capital and other items added $2.7M.
Questions
What was Citius Oncology's revenue in the third quarter fiscal 2026?
Citius Oncology (CTOR) reported revenue of $1.5M for the third quarter fiscal 2026 (Q3 FY26) and -10% from the quarter before.
Was Citius Oncology profitable in the third quarter fiscal 2026?
Operating loss was $8.7M (-583.5% of revenue) and net loss $8.9M.
Source: Citius Oncology 10-Q on SEC EDGAR.